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Impairment of platelet function commonly occurs after
cardiopulmonary bypass, and may result in substantial
bleeding. Because desmopressin acetate (a synthetic an-
alogue ofvasopressin) shortens bleeding time in a variety
of platelet disorders, a controlled clinical trial of intra-
venous desmopressin was performed in 39 patients with
excessive mediastinal bleeding (>100 ml/h) and a pro-
longed template bleeding time (>10 minutes) more than
2 hours after termination of cardiopulmonary bypass.
Twenty-three desmopressin recipients and 16control pa-
tients (no desmopressin) were similar in surgical pro-
cedure, pump time, platelet count, template bleeding
time and amount of bleeding before therapy (p = NS).
Compared with the control group, the patients re-
ceiving desmopressin (20 p.g; mean 0.3 p.g1kg) utilized
fewer blood products (29 ± 19 versus 15 ± 13
units/patient; p < 0.05), especially platelets (12 ± 9
versus 4 ± 7 units/patient; p = 0.004), while achieving
a similarly effective reduction in mediastinal bleeding
(4.8- and 4.3-fold, p = 0.001 for both). Severe platelet
dysfunction was partially corrected within I hour after
desmopressin infusion, during which interval no blood
products were administered: the template bleeding time
shortened (from 17 to 12.5 minutes, p < 0.05), whereas
the platelet count remained unchanged (at 96 ± 35 and
105 ± 31 x 103/mm3, p = NS). The plasma levels of
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two factor VIII components increased: procoagulant ac-
tivity (VIII:C) from 0.97 ± 0.43 to 1.52 ± 0.74 units/ml
(p < 0.05) and von Willebrand factor (VIII:vWF) from
1.28 to 1.78 units/ml (p < 0.05); these increases corre-
lated with the shortening of the bleeding time (p < 0.01).
In 10 (83%) of 12 patients who had continued bleeding
requiring reoperation, a localized bleeding source was
identified. Generalized mediastinal oozingat reoperation
was noted in only one patient each in the desmopressin
and control groups (p = NS).
In conclusion, administration of desmopressin re-
duced transfusion requirements and blood loss in pa-
tients with severe platelet dysfunction and bleeding after
cardiopulmonary bypass. Desmopressin simultaneously
shortened tbe bleeding time and increased circulating
plasma levels of the factor VIII complex (procoagulant
activity and von Willebrand factor), suggesting that the
beneficialeffects of desmopressin were mediated in part
by an elevation of plasma von Willebrand factor. Failure
of medical therapy (continued generalized bleeding re-
quiring reoperation) was infrequent, but the finding of
a localized bleeding source in a high proportion of re-
operations emphasizes the need for exquisite surgical
hemostasis at initial operation.
(1 Am Coli CardioI1987;9:1139-47)
Immediately after open heart surgery, mediastinal bleeding
is common and is related to vascular injury from surgical
incisions and to hemostatic abnormalities resulting from
cardiopulmonary bypass. Patients often require blood com-
ponent therapy, and if the bleeding remains excessive, me-
diastinal exploration may be necessary. Hemostastic ab-
normalities after cardiopulmonary bypass may be caused by
reductions in coagulation factors, inadequate reversal of
heparinization, excessive protamine administration, in-
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creased fibrinolytic activity, abnormal fibrin polymeriza-
tion, mild thrombocytopenia and defective platelet plug for-
mation (1- I9). Multiple qualitative abnormalities of platelet
function have been observed, including decreased platelet
adhesiveness, defective in vitro aggregation in response to
adenosine diphosphate (ADP) and collagen, a prolonged in
vivo template bleeding time, reduced membrane binding of
fibrinogen and alpha-adrenergic agonists, selective deple-
tion of alpha granules, and increased plasma levels of plate-
let constituents such as platelet factor 4 and beta-throm-
boglobulin 0-3,5,12-19). These abnormalities are primarily
due to platelet activation during passage through cardio-
pulmonary bypass components (oxygenator, roller pumps,
plastic tubing, cardiotomy suction and filters), are propor-
tional to the duration of bypass and are usually rapidly
reversible after its termination (1,17). However, several
studies (1-5) have demonstrated a severe, persistent func-
tional impairment of platelets in patients with a hemorrhagic
diathesis after open heart surgery, despite platelet counts
above lOO,000/mm3; blood loss and bleeding time have been
reduced by platelet transfusions.
Desmopressin (l-desamino-8-D-arginine vasopressin
rDDAVP]) is a synthetic analogue of vasopressin that, within
I hour after intravenous administration (0.3 to 0.4 jLg/kg)
in normal individuals, produces a two- to five-fold increase
in plasma levels of von Willebrand factor by causing its
release from storage sites (20-32). The von Willebrand
factor is one of the largest circulating plasma proteins and
plays a major role in mediating platelet adhesion to sub-
endothelium, especially at high shear rates, by binding to
specific receptors on the platelet membrane and to collagen
(33-39). By increasing plasma levels of von Willebrand
factor, desmopressin shortens bleeding time, improves he-
mostasis and reduces postoperative blood loss in patients
with a variety of platelet disorders. These include type I
von Willebrand's disease (a deficiency of von Willebrand
factor) (20-23), uremia (24,25) and aspirin-induced platelet
dysfunction (26). Improvement in hemostasis may occur
despite normal levels of von Willebrand factor before ther-
apy (24-26).
We believe that desmopressin might have a role in the
treatment of mediastinal bleeding when associated with se-
vere platelet dysfunction after cardiopulmonary bypass. The
purpose of our study was to determine whether, in this
setting, desmopressin reduces transfusion requirements, blood
loss and template bleeding time. In addition, we wished to
determine the effect of desmopressin on plasma levels of
von Willebrand factor after cardiopulmonary bypass.
Methods
Study patients. Patients who underwentopen heart sur-
gery at Cedars-Sinai Medical Center between July 1983 and
June 1985 were selected for study if they 1) had a normal
platelet count and template bleeding time preoperatively,
and 2) developed severe platelet dysfunction (template
bleeding time> 10 minutes) in association with significant
mediastinal bleeding (chest tube output> 100 mI/h) more
than 2 hours after termination of cardiopulmonary bypass.
Patients were excluded if they had a history of a bleeding
diathesis or a known factor deficiency, had used aspirin
within the prior 7 days, had received desrnopressin previ-
ously or had developed massive mediastinal hemorrhage
(>400 mI/h) requiring immediate reoperation. After these
exclusions, 39 patients fulfilled the criteria and entered the
study.
Thefirst 16 consecutive patients (July 1983 to June 1984)
constituted the control group and were treated with blood
products according to a standardized protocol based on the
first postoperative value of the template bleeding time, par-
tial thromboplastin time, prothrombin time and hematocrit
(obtained 2 hours after termination of bypass). Platelets (6
units) were administered for a template bleeding time of
> 10 minutes; fresh frozen plasma (2 units), for a partial
thromboplastin or prothrombin time> 1.2 X control and
cryoprecipitate (10 units) for persistent bleeding despite
platelet and fresh frozen plasma administration. Packed red
blood cells were given for a hematocrit of <30 (one unit)
or <25 (two units). If the patient continued to bleed ex-
cessively 2 to 4 hours later, blood product administration
was repeated according to the same criteria. Mediastinal
chest tube output and blood product utilization were mon-
itored hourly during the 24 hour period after entry into the
study. If bleeding continued to occur (> 100 ml/h, and cu-
mulative total> 1000 ml), then mediastinal exploration was
undertaken.
A second group of23 consecutive patients (July 1984 to
June 1985) received 20 jLg of desmopressin acetate (mean
0.3 jLg/kg body weight; DDAVP, USV Pharmaceuticals) in
50 ml normal saline solution administered intravenously
over 30 minutes. No blood products were administered dur-
ing or for I hour after desmopressin infusion. After this I
hour period, blood products were administered and if nec-
essary, mediastinal exploration was undertaken, according
to the same criteria specified for the control patients.
Anesthetic and surgical technique. Preoperative med-
ication consisted of morphine, atropine, scopolamine, ce-
fazolin (or vancomycin) and dipyridamole (75 to 100 mg).
With hemodynamic monitoring by central venous, radial
and pulmonary artery catheters, general endotracheal anes-
thesia was induced and maintained with enflurane or fen-
tanyl. After cannulation and systemic heparinization, car-
diopulmonary bypass was accomplished with a bubble
oxygenator (Bentley- 10, American Bentley) with a cardi-
otomy reservoir (BCR-3500, American Bentley). Non-blood
prime was Normosol; mannitol was administered during
cardiopulmonary bypass. Myocardial preservation consisted
of moderate systemic hypothermia (20 to 25°C) and inter-
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mittent multidose potassium cardioplegia with St. Thomas
solutionat 4°Cinfusedinto the aortic root or coronaryostia.
Coronary artery bypass grafting was accomplished with the
autologous reversed saphenous vein or internal mammary
artery. In 12 patients, valve replacement was performed
utilizingthe St. Jude (n = 8) or Hancock (n = 4) prosthesis,
After termination of cardiopulmonary bypass, heparin was
neutralized with protamine sulfate using a standardized pro-
tocol for all patients (1.0 to 1.5 mg/IOO units of heparin).
The interval from termination of cardiopulmonary bypass
to institution of treatment averaged 5.6 hours in each group
(p = NS).
Hematologic measurements. All patients underwent
preoperative and early postoperative measurement of he-
matocrit, platelet count, template bleeding time, partial
thromboplastin time and prothrombin time. Additional he-
matologic variables that were measured before the admin-
istration of desmopressin and at I, 4 and 24 hours after its
administration, included factor VIII procoagulant (Vlll.C)
activity, von Willebrand factor activity (VllI:vWF), fibrin-
ogen and fibrinogen-fibrin degradation products.
Template bleeding time determinations were performed
on the volar surface of the forearm with the Simplate II
device (General Diagnostics, Divisionof Warner-Lambert).
Platelet number was determined by a Coulter S&V elec-
tronic cell counter from venous blood collected in ethyl-
enediaminetetraacetate (EDTA).
Plasma samples were prepared from venous blood col-
lected in 3.8% sodiumcitrate (I part citrate: 9 parts blood),
transported on ice and centrifuged at 3,000 rpm at 4°C for
15minutes. Factor VIII procoagulant (FVIII:C) activitywas
assayed on fresh plasma samples by a modification of the
partial thromboplastin time utilizing factor VIII deficient
plasma as a substrate (40). Results wereexpressed as units/ml
(normal range 0.5 to 1.5). Von Willebrand factor (VIII:
vWF- also known as VIII-related antigen) was assayed by
electroimmunodiffusion utilizing fresh or frozen citrated
plasma and monospecific rabbit antiserum (Calbiochem-
Behring). Results were expressedas units/ml (normal range
0.5 to 1.5). The prothrombin time, partial thromboplastin
time, fibrinogen (normal range 150 to 400 mg/dl) and fi-
brinogen-fibrin degradation products (latex agglutination,
normal range < 10 j.tg/ml) were performed by standard
methods (40).
Statistical methods. Comparisons of continuous vari-
ables between the desmopressin and control groups were
made with the unpaired two-tailed t test, or by the nonpar-
ametric Mann-Whitney U test if the F test for variances was
significant at the 0.05 level. Comparisons among repeated
measurements of continous variables (in the desmopressin
group) were made with Friedman's nonparametric analysis
of variance (ANOVA) followed by Neuman-Keuls multiple
comparisons if the ANOVA F statistic probability was <0.05.
Changes in mean hourly chest tube output (before study
entry versus the 24 hour period afterward) in each treatment
group were assessed using the Wilcoxon rank-sum test.
Categorical variableswerecomparedby meansof chi-square
analysisor by Fisher's exact test. All statistical calculations
Table l. Baseline Comparison of Selected Preoperative, Operative and Early Postoperative
Variables in the Desmopressin and Control Groups
Desmopressin Control
Variable (n = 23) (n = 16) P Value
Preoperative
Age (yr) 6H ± 8 72 ± 8 NS
Prior cardiac surgery 5(22%) 2(13%) NS
Hematocrit (%) 40 ± 4 38 ± 6 NS
Platelet count (IO'/mm') 254 ± 65 238 ± 69 NS
Bleeding time (min) 4.0 ± 1.6 4.0 ± 1.5 NS
Partial thromboplastin time (s) 28.6 ± 4.1 34.0 ± 11.2 NS
Prothrombin time (s) 10.4 ± 0.6 10.8 ± 0.9 NS
Operative
Duration of bypass (min) 156 ± 47 155 ± 45 NS
Procedure
Revascularization 17(74%) 10(63%)
Valve replacement 2(9%) 2(13%) NS
Both 4(17%) 4(25%)
Early postoperative
Hematocrit (%) 28 ± 4 31 ± 8 NS
Platelet count ( 1O'/mm') 96 ± 35 92 ± 49 NS
Bleeding time (min) 17 (10 to >30) 19 (II to >30) NS
Partial thromboplastin time (s) 52.4 ± 18.4 47,9 ± 17.4 NS
Prothrombin time (s) 12.6 ± 1.0 13.1 ±1.8 NS
Core temperature (OF) 94.8 ± 3.4 95.8 ± 3.1 NS
Mediastinal tube output (cc/h) 186 ± II'! 264 ± 153 NS
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were performed with BMDP statistical software (41), and
the alpha level for all univariate analyses was set at 0.05.
Values of normally distributed continuous variables are
summarized in the tables and figures as mean ± SD. Values
not normally distributed and those measured on an ordinal
scale are summarized as median and range.
Results
Baseline comparison (Table 1). The 23 patients who
received desmopressin were comparable to the 16 control
patients in terms of age, incidence of prior cardiac surgery,
preoperative hematocrit, platelet count, template bleeding
time, partial thromboplastin and prothrombin times. There
was no significant difference between the desmopressin and
control groups in the duration of cardiopulmonary bypass,
type of surgery performed, early postoperative hematologic
profile (hematocrit, platelet count, template bleeding time,
partial thromboplastin and prothrombin times) or tempera-
ture (all p > 0.05). The mediastinal tube output was sim-
ilarly high in both groups, at 186 and 264 mllh, respectively
(p > 0.05). All patients had a severe acquired platelet dys-
function, as evidenced by postoperative bleeding times of
17 and 19 minutes, respectively, despite normal preopera-
tive values.
Postoperative bleeding, blood product utilization and
reoperation (Table 2). During the 24 hour period after
treatment, mediastinal tube outputs were reduced 4.3- and
4.8-fold, to 43 and 55 mllh, respectively, in the desmo-
pressin and control groups. These values were significantly
lower than the baseline pretreatment outputs (p < 0.001 for
each) but were not significantly different between the des-
mopressin and control groups (p = NS). Therefore, both
treatments were equally effective in reducing bleeding.
Overall blood product utilization was significantly less
in the desmopressin group (15 units/patient, compared with
29 units/patient in the control group; (p < 0.05). Of the
individual blood components, the most marked reduction
was observed in platelet usage, with a threefold reduction,
from 11.8 to 4.0 units/patient (p = 0.004). There was also
a reduction in utilization of fresh frozen plasma and cry-
oprecipitate, which did not reach statistical significance, and
a significant reduction in red cell usage in the desmopressin
group (p < 0.05).
Only 2 patients in the desmopressin group required re-
operation, compared with 12 in the control group (p =
0.001). However, the bleeding had stopped during sterno-
tomy in two of the control patients. In 10 of the remaining
12 patients who had continued bleeding at reoperation, a
localized bleeding source treatable with surgical ligation was
identified. Generalized mediastinal oozing at reoperation
was noted in only one patient each in the desmopressin and
control groups (l of 23 versus 1 of 16, P = NS). Thus,
"treatment failures" (failure to stop generalized bleeding
and avoid mediastinal exploration despite medical therapy
for platelet dysfunction) occurred infrequently in the des-
mopressin and control groups (4 and 6%, respectively; p =
NS).
Changes in hematologic variables after desmopressin
(Fig. 1 and 2, Table 3). To elucidate the mechanism by
which desmopressin achieves a reduction in bleeding and
blood product utilization, we measured hematologic vari-
ables immediately before desmopressin administration and
at 1, 4 and 24 hours afterward. The postoperative predes-
mopressin value served as a control value with which all
other measurements were compared.
The template bleeding time, which was quite prolonged
(median 17 minutes) early postoperatively, demonstrated
Table 2. Postoperative Bleeding, Blood Product Utilization and Reoperation Rates in
Desmopressin and Control Groups AfterTreatment
Desmopressin Control p
(n = 23) (n = 16) Value*
Mediastinal tube output (cc/h)" 43 ± 25 55 ± 27 NS
Blood product utilization
(units/patient)
Platelets 4.0 ± 6.7 11.8±9.1 0.004
Fresh frozen plasma 2.7 ± 2.8 4.2 ± 2.6 NS
Cryoprecipitate 0.4 ± 2.1 2.5 ± 5.8 NS
Red blood cells 4.8 ± 3.0 7.9 :!:: 4.7 0.015
Cell saver 3.4 ± 1.0 2.9 :!:: 1.8 NS
Total 15.3 :!:: 13.4 29.2 :!:: 19.3 0.02
Hematocrit after 24 hours (%) 28 ± 3 29 :!:: 2 NS
Reoperation for hemorrhage 2(9%) 12(75%) 0.001
Generalized bleeding I I
Localized bleeding I 9
Bleeding stopped 0 2
*Desmopressin versus control; treduced significantly compared with baseline pretreatment measurement (p
= 0.(01), but not significantly different between desmopressin and control groups.
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Table 3. Selected Laboratory Measurements Before and After Desmopressin Administration in
23 Patients
Postoperative
Before
Preoperative Desmopressin
Partial thromboplastin
time (s)
Prothrombin time (s)
Fibrinogen (mg/dl)
Fibrinogen-fibrin
degradation products
(no. > 10 ILg/ml)
Hematocrit (%)
Serum sodium
(mEq/liter)
Serum creatinine (mg/dl)
29 ± 4*
10.4 ± 0.6*
40 ± 4*
140 ± 3
1.3 ± 0.4*
52 ± 18
12.6 ± 1.0
154 ± 70
4
28 ± 4
141 ± 3
1.1 ± 0.4
After Desmopressin
I Hour 4 Hours 24 Hours
48 ± 25* 45 ± 12* 39 ± 13*
12.3 ± 1.1 11.6 ± 0.8* 11.2 ± 1.4*
162 ± 57 179 ± 62* 288 ± 73*
5 8 2
28 ± 3
140 ± 4
1.3 ± 0.4*
*p < 0.05 compared with postoperative value before desmopressin.
Figure 1. Platelet count and template bleeding time in 23 patients,
determined preoperatively (PREOP), early postoperatively
(POSTOP PRE DDAVP) and at I, 4 and 24 hours after desmo-
pressin administration (POSTOP, POST DDAVP), Asterisks in-
dicate mean or median values that are significantly different from
early postoperative pre-DDAVP values, Shaded area on vertical
axis references the normal range.
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significant shortening at I and 4 hours after the administra-
tion of desmopressin, and showed no significant further
shortening by 24 hours (Fig. I, lower panel), The mean
platelet count remained unchanged at 90,000 to lOO,000/mm3
after desmopressin (Fig, I, upper panel).
Factor VIII procoagulant (VIII:C) activity demonstrated
a significant increase at I and 4 hours after desmopressin,
frequently to supernormal values (Fig, 2, upper panel), There
was a slight drop-off at 24 hours, but significant augmen-
tation remained. Likewise, von Willebrand factor activity
(VIII:vWF) demonstrated significant increases at I, 4 and
24 hours after desmopressin administration (Fig, 2, lower
panel),
The partial thromboplastin time, which was prolonged
immediately postoperatively, demonstrated shortening within
I hour after desmopressin administration and at later inter-
vals as well (Table 3), There was no significant change in
prothrombin time or fibrinogen level during the first hour
after desmopressin infusion, Fibrinogen levels rose signif-
icantly at 4 and 24 hours, ruling out significant activation
of the fibrinolytic system despite appearance of fibrinogen-
fibrin degradation products in low titer (10 to 40 J,Lg/ml) in
some patients during the study,
The hematocrit and serum sodium remained unchanged
before and after administration of desmopressin. The serum
creatinine level increased slightly after desmopressin, but
precisely to the level of its preoperative value,
Correlation of changes in hematologic variables dur-
ing the first hour after desmopressin infusion. Within 1
hour after desmopressin administration, the shortening of
the template bleeding time correlated significantly with in-
creases in factor VIII procoagulant (VIII:C) and von Wil-
lebrand factor (VIII:vWF) activity, and a shortening of the
1 HR 4 HR 24 HR
POSTOP. POST DDAVP
1 HR 4 HR 24 HR
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Figure 2. FactorVIIIprocoagulant (FVIII:C) and von Willebrand
factor (VIII:vWF) activities in 23 patients, determined early post-
operatively (POSTOP PRE DDAVP) and at I, 4 and 24 hours
afterdesmopressin administration (POSTaP, POSTDDAVP). The
asterisks indicate mean or median values significantly different
from the early postoperative pre-DDAVP value. Shaded area on
vertical axis references the normal range.
partial thromboplastin time (p < 0.01). There was no cor-
relation of the shortened bleeding time with platelet count,
prothrombin time or fibrinogen level (p = NS).
Perioperative infarction rates and in-hospital mor-
tality (Table 4). Perioperative infarction was diagnosed by
the appearance of a new Q wave (0.04 s or longer in du-
ration) in at least one ECG lead, or by the appearance of
>80 IV creatine kinase (MB fraction) in the serum (42).
The rate of perioperative infarction in the desmopressin
group (9%) was lower than that of the control group (19%),
but this difference was not statistically significant. There
was one in-hospital death in the desmopressin group (4%)
and there were three such deaths (19%) in the control group
(p = NS). No deaths were due to myocardial infarction.
Discussion
Effects of desmopressin after cardiopulmonary by-
pass. Our study demonstrates that desmopressin is an ef-
fective therapy for severe platelet dysfunction and bleeding
after cardiopulmonary bypass. Desmopressin reduced total
blood product utilization by half (from 29 ± 19 to 15 ±
13 units/patient; p = 0.02). The most marked reduction
was observed in platelet usage, which decreased threefold
(from 12 ± 9 to 4 ± 7 units/patient; p = 0.004) (Table
2). At the same time, mediastinal bleeding was reduced as
effectively in the desmopressin group as in the control group.
Within I hour after desmopressin infusion (during which
interval no blood products were administered), there was a
reduction in template bleeding time from 17 to 12.5 minutes
(p < 0.05) (Fig. 1). This shortening of bleeding time cor-
related significantly (p < 0.01) with simultaneous increases
in von Willebrand factor and factor VIII procoagulant ac-
tivities (Fig. 2) and a shortening of the partial thromboplastin
time (Table 3). The plasma levels of factor VIII procoa-
gulant after cardiopulmonary bypass are adequate to main-
tain normal hemostasis (1,12), and increases may shorten
the partial thromboplastin time but do not affect the template
bleeding time. This suggests that desmopressin achieved a
shortening of bleeding time by increasing plasma levels of
von Willebrand factor, with a resultant improvement in platelet
adhesion. Desmopressin may preferentially augment release
of the large multimers of von Willebrand factor which are
the most effective in mediating platelet adhesion
(22,24,33,37).
Platelet functional improvement occurred after desmo-
pressin administration despite normal or above normal von
Willebrand factor levels in most patients before therapy
(Fig. 2); similar findings have been previously described in
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Table 4. Perioperative Infarction Rates and In-Hospital Mortality Rates in Desmopressin and
Control Groups
Desmopressin
(n = 23)
Control
(n 0= 16) p Value
Perioperative infarction
CABG
CABG + valve replacement
Valve replacement
In-hospital deaths
2(9%)
2/16(12.5%)
0/5(0%)
0/2(0%)
1(4%)
3(19%)
2/10(20%)
1/4(25%)
0/2(0%)
3(19%)
NS
NS
CABG = coronary artery bypass grafting.
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patients with uremia (24,25) or aspirin-induced platelet dys-
function (26), and in hemostatically normal individuals
undergoing spinal fusion surgery (43), Thus, a low von
Willebrand factor level is not required for a beneficial re-
sponse to desmopressin. Nonetheless, a relatively low pre-
operative level of von Willebrand factor predicts a hem-
orrhagic tendency postoperatively, supporting a role for von
Willebrand factor in the bleeding disorder after cardiopul-
monary bypass (44).
All patients in this series had a normal template bleeding
time before surgery. The subsequently acquired platelet dys-
function was severe (bleeding time > 10 minutes) and sus-
tained (>2 hours) after termination of cardiopulmonary by-
pass, and was attributable to the long pump times (mean
156 minutes) in the study group compared with other cardiac
surgical patients who did not develop mediastinal bleeding
during a concurrent time period (p < 0.05). This is con-
sistent with the previously published reports relating severe
sustained platelet dysfunction to prolonged hypothermic car-
diopulmonary bypass (l ,2, 17,45).
The routine preoperative administration ofdipyridamole
is unlikely to explain the increased tendency to bleeding
and platelet dysfunction in either the desmopressin or the
control group because all patients at our institution receive
dipyridamole preoperatively, whereas only a fraction of them
manifest severe postoperative bleeding; and dipyridamole
given preoperatively may have a platelet-sparing effect and
did not increase postoperative bleeding in a double-blind,
randomized trial (46,47). What is suggested, however, is
that desmopressin effectively shortens bleeding time and
reduces blood product utilization despite prior administra-
tion of antiplatelet drugs (26),
The improvement in platelet adhesion resulting from des-
mopressin administration overcomes, only in part, the plate-
let functional defects that occur after cardiopulmonary by-
pass (48,49). Desmopressin probably has no direct effect
on platelet alpha granule depletion. In support of this, plate-
let functional improvement was incomplete, as indicated by
the continued prolongation of the template bleeding time in
many patients I and 4 hours after desmopressin infusion
(Fig. I).
The effectiveness ofdesmopressin in reducing blood loss
after cardiac surgery has been recently confirmed by Salz-
man et al. (44) in a double-blind, randomized trial. How-
ever, their patients received desmopressin even if platelet
function after cardiopulmonary bypass was normal (mean
template bleeding time 7.58 ± 2.9 minutes) and bleeding
was not excessive. Such prophylactic use of desmopressin
for nonbleeding patients with normal platelet function may
not be justifiable after coronary artery bypass grafting, given
the susceptibility of fresh saphenous vein grafts to early
thrombosis (50).
The perioperative infarction rate in our desmopressin
group (9%) was comparable with that reported in clinical
studies of bypass graft patency (46). The perioperative in-
farction rate in the control group was higher (19%) (Table
4), suggesting that the additional blood products (especially
platelets) given to the control group may have been detri-
mental, but this effect was not strong enough to reach sta-
tistical significance. Nevertheless, graft angiography was
not performed and therefore conclusions regarding the issue
of graft patency remain indeterminate from this study.
Potential savings in blood product utilization with des-
mopressin use. Between November 1981 and July 1984,
1,935 adult open cardiac procedures were performed at Ce-
dars-Sinai Medical Center. The reoperation rate for bleeding
during this time was 7% (132 patients). During 1983,191,000
coronary artery bypass operations were reported to the Na-
tional Hospital Discharge Survey of the National Center for
Health Care Statistics (51). If the nationwide reoperation
rate is approximately 7%, then 13,400 patients would re-
quire reexploration yearly, and the projected blood product
utilization would be approximately 130,000 units of plate-
lets, 100,000 units of packed red cells and 53,600 units of
fresh frozen plasma, if the patterns of blood product utili-
zation are similar to our own. Wider use of desmopressin
could potentially save 87,000 units of platelets, 50,000 units
of packed red cells and 27,000 units of fresh frozen plasma
yearly, substantially reducing not only blood product uti-
lization after open heart surgery, but also the risks of trans-
fusion-related diseases and infections.
Reoperations. A generalized pattern of bleeding was
observed at reoperation in only one patient each in the des-
mopressin and control groups, demonstrating that failure of
medical therapy (requiring reoperation) was infrequent in
both groups (4 and 6%, p = NS). However, in the remaining
10 (83%) of 12 patients who had continued bleeding re-
quiring reoperation, a localized bleeding source was iden-
tified. This finding emphasizes the need for exquisite sur-
gical hemostasis before chest closure at initial operation. A
further reduction in blood product usage even without the
use of desmopressin could potentially be achieved with this
attention to detail. Nevertheless, of all 39 patients in the
study population, only 26% (10) had an identifiable local-
ized bleeding source; the remaining 74% (29) presumably
had generalized oozing, which responded to medical therapy
in all but two cases,
Other considerations. Although treatment in this pro-
spective study was not blinded or randomized, the des-
mopressin and control groups were well matched in all 16
measured preoperative, operative and early postoperative
variables, thus assuring comparability of the two groups.
Further, the interval from termination of cardiopulmonary
bypass to initiation of therapy in both groups was identical
(5.6 hours), thus ruling out differences in the timing of
therapy.
We observed no adverse consequences of desmopressin
on renal function or water metabolism, as measured by
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serum creatinine and sodium levels (Table 3), nor any changes
in heart rate or blood pressure. However, small transient
effects of desmopressin on these variables cannot be ruled
out by our study. Previous experience with the use of this
drug in treatment of von Willebrand's disease, hemophilia
and diabetes insipidus (52) has confirmed only infrequent
side effects of facial flushing and transient small rises in
blood pressure. There was no decrease in the fibrinogen
level after desmopressin infusion (Table 3), a theoretical
possibility because of the augmentation of plasminogen ac-
tivator release by desmopressin (29-32).
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